CMS releases negotiated price list
-
Oddly, I've heard of none of these. I'm usually close enough to Pharma news (daily digests from trade rags, etc) to see names of common treatments.
2026 Prices for Drugs Subject to Negotiations
Prices are the maximum Medicare Part D plans and the patient will pay for a one-month supply.
-
Eliquis, for preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer, $231
-
Jardiance, for diabetes and heart failure, from Boehringer Ingelheim and Eli Lilly, $197
-
Xarelto, for preventing strokes and blood clots, from Johnson & Johnson, $197
-
Januvia, for diabetes, from Merck, $113
-
Farxiga, for diabetes, heart failure and chronic kidney disease, from AstraZeneca $178
-
Entresto, for heart failure, from Novartis, $295
-
Enbrel, for autoimmune conditions, from Amgen, $2,355
-
Imbruvica, for blood cancers, from AbbVie and Johnson & Johnson, $9,319
-
Stelara, for autoimmune conditions, from Johnson & Johnson, $4,695
-
Fiasp and NovoLog insulin products, for diabetes, from Novo Nordisk, $119
"You never know what worse luck your bad luck has saved you from."
-Cormac McCarthy -
-
https://www.politico.com/news/2024/08/15/cms-releases-prices-for-10-negotiated-drugs-00174021
The result is a $6 billion savings across 10 drugs when new prices take effect in 2026, according to the White House, and beneficiaries could save roughly $1.5 billion in out-of-pocket costs.
-
Oddly, I've heard of none of these. I'm usually close enough to Pharma news (daily digests from trade rags, etc) to see names of common treatments.
2026 Prices for Drugs Subject to Negotiations
Prices are the maximum Medicare Part D plans and the patient will pay for a one-month supply.
-
Eliquis, for preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer, $231
-
Jardiance, for diabetes and heart failure, from Boehringer Ingelheim and Eli Lilly, $197
-
Xarelto, for preventing strokes and blood clots, from Johnson & Johnson, $197
-
Januvia, for diabetes, from Merck, $113
-
Farxiga, for diabetes, heart failure and chronic kidney disease, from AstraZeneca $178
-
Entresto, for heart failure, from Novartis, $295
-
Enbrel, for autoimmune conditions, from Amgen, $2,355
-
Imbruvica, for blood cancers, from AbbVie and Johnson & Johnson, $9,319
-
Stelara, for autoimmune conditions, from Johnson & Johnson, $4,695
-
Fiasp and NovoLog insulin products, for diabetes, from Novo Nordisk, $119
@jon-nyc said in CMS releases negotiated price list:
Oddly, I've heard of none of these. I'm usually close enough to Pharma news (daily digests from trade rags, etc) to see names of common treatments.
2026 Prices for Drugs Subject to Negotiations
Prices are the maximum Medicare Part D plans and the patient will pay for a one-month supply.
- Eliquis, for preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer, $231
$1.51 per pill in the Philippines.
- Jardiance, for diabetes and heart failure, from Boehringer Ingelheim and Eli Lilly, $197
$1.02 per pill in the Philippines.
- Xarelto, for preventing strokes and blood clots, from Johnson & Johnson, $197
$2.70
- Enbrel, for autoimmune conditions, from Amgen, $2,355
$465 per bottle.
Do I need to go on?
-
-
No everyone knows about price discrimination among nations and most people, after thinking it through, are fine with it to a certain degree at least.
I would love to see a law that says Medicare won’t pay more than the average G7 country. It’s reasonable to have the rich countries pay their share of drug development costs, US has no business subsidizing them.
The poorest countries are another matter.
-
Buy a Yamaha piano.
Don't know if it's still this way, but the cost difference on a U1 between the U.S. and Mexico was considerable, years ago...
“Cry havoc and let slip the DOGE of war!”
Those who cheered as J-6 American prisoners were locked in solitary for 18 months without trial, now suddenly fight tooth and nail for foreign terrorists’ "due process". — Buck Sexton
-
Thing about most drugs is the difference between the fixed cost and the marginal cost is beyond extreme.
The stylized version is “the first pill costs a billion dollars, the 2nd pill costs $1.”
In the world we live in, the US pays most of the bill of that fixed (development) cost. The other rich countries pay a minority and the poorest countries pay the marginal cost or less.
If we had a law that prohibited price discrimination that would basically mean that 2/3 of humanity or more wouldn’t have access to modern pharmaceuticals.
Most people are ok with the idea that the rich world covers the development cost and the poorest don’t. But the heavy subsidies the US gives Europe are rather obscene.
I don’t want the US to pay European drug prices, for purely selfish reasons. There are 20+ active programs in my indication only because they can charge 150k+ a year to a rare disease population. Rather, I want the Europeans to pay more while we pay less. IOW meet in the middle while leaving incentives for innovation the same.
-
Buy a Yamaha piano.
Don't know if it's still this way, but the cost difference on a U1 between the U.S. and Mexico was considerable, years ago...
@Jolly said in CMS releases negotiated price list:
the cost difference on a U1 between the U.S. and Mexico
The problem is that, when a piano that’s intended for a moist climate is placed in a dry environment, there is the likelihood that its structural integrity will be threatened as the wooden parts lose moisture. This in turn can cause warping of case parts, cracks in the soundboard and/or loose tuning pins.
-
Yeah, but...
How many new drugs does the developing world need? Let's take something like erythromycin...For years erythromycin was dirt cheap, especially when compared with zithromax. Erythromycin had the disadvantage of more frequent and more total doses, but both antibiotics were killing essentially the same bugs.
There are multiple drugs like that out there and I suspect physicians in those countries often choose the cheapest drug that is effective.
I think it's going to be very interesting when the patents run out on the first-generation biologicals.
“Cry havoc and let slip the DOGE of war!”
Those who cheered as J-6 American prisoners were locked in solitary for 18 months without trial, now suddenly fight tooth and nail for foreign terrorists’ "due process". — Buck Sexton
-
@Jolly said in CMS releases negotiated price list:
the cost difference on a U1 between the U.S. and Mexico
The problem is that, when a piano that’s intended for a moist climate is placed in a dry environment, there is the likelihood that its structural integrity will be threatened as the wooden parts lose moisture. This in turn can cause warping of case parts, cracks in the soundboard and/or loose tuning pins.
@Copper said in CMS releases negotiated price list:
@Jolly said in CMS releases negotiated price list:
the cost difference on a U1 between the U.S. and Mexico
The problem is that, when a piano that’s intended for a moist climate is placed in a dry environment, there is the likelihood that its structural integrity will be threatened as the wooden parts lose moisture. This in turn can cause warping of case parts, cracks in the soundboard and/or loose tuning pins.
Third rail kinda guy, eh?
-
Yeah, but...
How many new drugs does the developing world need? Let's take something like erythromycin...For years erythromycin was dirt cheap, especially when compared with zithromax. Erythromycin had the disadvantage of more frequent and more total doses, but both antibiotics were killing essentially the same bugs.
There are multiple drugs like that out there and I suspect physicians in those countries often choose the cheapest drug that is effective.
I think it's going to be very interesting when the patents run out on the first-generation biologicals.
@Jolly said in CMS releases negotiated price list:
Yeah, but...
How many new drugs does the developing world need? Let's take something like erythromycin...For years erythromycin was dirt cheap, especially when compared with zithromax. Erythromycin had the disadvantage of more frequent and more total doses, but both antibiotics were killing essentially the same bugs.
There are multiple drugs like that out there and I suspect physicians in those countries often choose the cheapest drug that is effective.
Mostly for diseases we can’t now cure. Gene therapies for sickle cell anemia are in trials now. Africa is the largest market by patient count. US by dollar volume.
I think it's going to be very interesting when the patents run out on the first-generation biologicals.
Depends on which. Plasma products, for example, are very different as there are actual diseconomies of scale. (To get a marginal new plasma donor generally costs more than your existing donors). So the economics are very different.
(By the way, gene therapies are considered biologics by the FDA so they’ll stay relevant for the foreseeable future)
